Jim Clemmer: Yes, Jason, it’s Jim. Just some of the feedback we’ve received now that AngioVac has been on the market for just over a year. We’ve got some great feedback on how it works, the safety and efficacy that it gives to the physicians, but you always get good feedback. So we’re looking at making some product enhancements as anybody would do on a 2.0 version, adding some things. We expect some of those enhancements to be launched in calendar 2025 — I’m sorry, Jason, calendar 2024. I get confused on our fiscal year. Next calendar year.
Jason Bedford: Okay. Thank you.
Jim Clemmer: Thanks, Jason.
Operator: Our next question is coming from the line of Bill Plovanic with Canaccord Genuity. Please proceed with your question.
Bill Plovanic: Great, thanks for taking my questions. Good morning. First off, just the Auryon product, the uses seem to be expanding as you talk about the thrombectomy and then going into coronary. Just trying to kind of get wrap my head around. One, as we look at the business today, that was really solid growth. How much of that was U.S. versus OUS driven? How much of that is outpatient versus OBL? And then just two, how should we think about this strategically as you move forward? It seems like this product is becoming a bigger and bigger piece of the company’s overall Med Tech franchise in finding more uses.
Jim Clemmer: Yes. So, Bill, good question. So first of all, almost every dollar of revenue that we had in 2023 was in the U.S. So we’re gaining our CE mark as we speak. We said we expect that in the first half of this fiscal year. There was some research that was done in Europe and some of that was been published, we’ve talked about it, by some clinicians and physicians in Europe, who are really excited by Auryon. We look forward to seeing what they’re doing. But almost all that was U.S. based. And second, we’re running now at a clip, I call it, 75% OBL revenue and 25% hospital revenue. That’s increasing. The hospital percentage is increasing as we speak, which we would expect. As you know, we launched in September of 2020. During the pandemic, it was harder to get access in the hospitals at the time.
So our initial customers are OBL related, but we’re watching that mix balance a bit more towards the hospitals. And finally, Bill, your question is a great one. When we acquired Eximo Medical, we believed in what it could do in this market, in the PAD market, and challenging the four good companies that we compete with. These guys are good companies with good products. But we knew what Auryon did was special and could create a spot in the market. We’re proving that. We also knew how it works, the mechanism of action and the science behind it could be applicable in other parts of the anatomy in other disease states. And that’s what we now have a lot of confidence in. So talking about launching the venous version in FY — sorry, in calendar year 2025 is important to us as we’ll round out our thrombectomy portfolio with Auryon in that small vessel platform.
And also, Bill, we really believe as well as it works in peripheral artery disease. We can do the same thing in coronary, giving doctors that safety they require treating coronary indications and also the power of how Auryon delivers the energy within that vessel wall to break up calcium and clot. So that will be part of our future as you identified.
Bill Plovanic: And then given the moving into these new indications, are there major studies that we should be tracking? How do we think about that? And then just on the AlphaVac, that seems obviously to be going a little slower than original expectations. How — is that until we get the F18 for PE, you’re going to be kind of hands tied behind your back on that one in terms growth? How should we think about that until the PE indication comes?
